2024-12-19 - Analysis Report
## LLY (Eli Lilly and Co) Stock Analysis Report

**1. Relative Performance vs. S&P 500:**

Eli Lilly and Co (LLY), a global pharmaceutical company, has significantly outperformed the S&P 500 (VOO). LLY's cumulative return is 565.87% compared to VOO's 120.85%, resulting in a difference of 445.02%. The Relative Divergence Indicator (RDI) stands at 71.2, suggesting LLY's performance is in the higher percentiles of its historical range compared to the S&P 500.  Alpha has consistently increased over the analyzed periods, indicating strong outperformance beyond market movements.

**2. Recent Price Movement:**

LLY's closing price is $778.62, slightly above the last market price of $777.83.  Short-term moving averages (5-day and 20-day) are slightly above the current price, indicating potential downward pressure. The 60-day moving average ($840.90) is significantly higher, suggesting a longer-term uptrend but a recent pullback.

**3. Technical Indicators:**

* RSI: 45.12 - Suggests the stock is neither overbought nor oversold, indicating a neutral momentum.
* PPO: 0.0931 - A positive PPO suggests bullish momentum, though the low value suggests a weak trend.
* Relative Divergence Change (20-day): -2.8 -  Indicates a decreasing divergence from the S&P 500, suggesting a relative weakening in performance over the short term.
* Expected Return: 567.5% -  Indicates a very high potential for outperformance against the S&P 500 over the long term (2+ years).


**4. Recent Earnings Analysis:**

* **Latest Quarter Comparison:** Revenue increased significantly in the most recent quarter (2024-10-30) compared to the previous quarters. EPS also saw improvement but was notably lower than the Q2 2024 value.
* **Revenue Growth Trends:**  Revenue shows an overall upward trend, with notable growth in recent quarters.
* **EPS Trends:** EPS fluctuated, with a significant increase in Q2 2024 followed by a decline in the most recent quarter.  The negative EPS in Q4 2023 and its recurrence in Q3 2024 (based on the data provided - this appears to be an error in the table provided) warrants further investigation.
* **Beats/Misses:**  The provided data doesn't include analyst expectations, making it impossible to assess beats or misses.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue has been growing consistently.  Profit margin remains remarkably high and stable.
* **Capital and Profitability:**  Equity has increased steadily. ROE shows volatility, with a significant increase in Q2 2024 but fluctuating performance in other quarters.  The negative ROE in Q3 2023 needs further investigation.


**6. News and Recent Issues:**

* **Earnings News:**  The analysis covers the latest earnings release (2024-10-30).  Further details on market reactions and expert commentary should be consulted from reputable financial news sources.
* **Market Outlook and Analyst Opinions:** To gain a comprehensive perspective, recent market outlook reports and analyst opinions specific to LLY should be reviewed from reliable sources.

**7. Summary:**

LLY has demonstrated strong historical performance compared to the S&P 500. Recent financial results show continued revenue growth and high-profit margins. However, fluctuations in EPS and ROE require further investigation.  Technical indicators suggest a neutral near-term outlook with some potential downward pressure. The long-term expected return remains highly positive.  Reviewing recent news, market outlook reports, and analyst opinions is crucial for informed decision-making.

**8. Disclaimer:** This report is based solely on the provided data and should not be considered financial advice. It's essential to conduct thorough research and consult with a qualified financial advisor before making any investment decisions.
